BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control

References

• WHO. Global leprosy situation, beginning 2008. Wkly Epidemiol. Rep.33, 293–300 (2008).
   Google Scholar
• Setia MS, Steinmaus C, Ho CS, Rutherford GW. The role of BCG in prevention of leprosy: a meta-analysis. Lancet Infect. Dis.6(3), 162–170 (2006).
   PubMed Web of Science ®Google Scholar
• Velema JP, Ogbeiwi OI. ILEP organisations should strive for high BCG coverage in communities at risk of leprosy. Lepr. Rev.78(2), 88–101 (2007).
   PubMedGoogle Scholar
• Zodpey SP. Protective effect of bacillus Calmette Guerin (BCG) vaccine in the prevention of leprosy: a meta-analysis. Indian J. Dermatol. Venereol. Leprol.73(2), 86–93 (2007).
   PubMed Web of Science ®Google Scholar
• Fine PE, Vynnycky E. The effect of heterologous immunity upon the apparent efficacy of (e.g. BCG) vaccines. Vaccine16(20), 1923–1928 (1998).
   PubMedGoogle Scholar
• Greenland S. Chapter 32. Meta-analysis. In: Modern Epidemiology. Rothman KJ, Greenland S (Eds). Lippincott-Raven Publishers, PA, USA, 643–673 (1998).
   Google Scholar
• Deeks JJ, Altman DG, Bradburn MJ. Chapter 15. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Systematic Review in Health Care. Meta-analysis in Context. Egger M, Smith GD, Altman DG (Eds). BMJ Publishing Group, London, UK, 285–312 (2001).
   Google Scholar
• Sutton AJ, Abrams KR, Jones DR, Sheldom TA, Song F. Methods for Meta-analysis in Medical Research. John Wiley & Sons Ltd, Chichester, UK (2000).
   Google Scholar
• Thompson SG, Higgins JBT. How should meta-regression analysis be undertaken and interpreted? Stat. Med.21, 1559–1573 (2002).
   PubMed Web of Science ®Google Scholar
• Bagshawe A, Scott GC, Russell DA, Wigley SC, Merianos A, Berry G. BCG vaccination in leprosy: final results of the trial in Karimui, Papua New Guinea, 1963–79. Bull. World Health Organ.67(4), 389–399 (1989).
   PubMedGoogle Scholar
• Gupte MD. Field trials of antileprosy vaccines. Indian J. Lepr.70(4), 363–367 (1998).
   PubMedGoogle Scholar
• Lwin K, Sundaresan T, Gyi MM et al. BCG vaccination of children against leprosy: fourteen-year findings of the trial in Burma. Bull. World Health Organ.63(6), 1069–1078 (1985).
   PubMedGoogle Scholar
• Stanley SJ, Howland C, Stone MM, Sutherland I. BCG vaccination of children against leprosy in Uganda: final results. J. Hyg. (Lond.)87(2), 233–248 (1981).
   PubMedGoogle Scholar
• Tripathy SP. The case for B.C.G. Ann. Natl Acad. Med. Sci.19(1), 11–21 (1983).
   PubMedGoogle Scholar
• Cunha SS, Rodrigues LC, Pedrosa V, Dourado IM, Barreto ML, Pereira SM. Neonatal BCG protection against leprosy: a study in Manaus, Brazilian Amazon. Lepr. Rev.75(4), 357–366 (2004).
   PubMedGoogle Scholar
• de Matos HJ, Duppre N, Alvim MF, MachadoVieira LM, Sarno EN, Struchiner CJ. [Leprosy epidemiology in a cohort of household contacts in Rio de Janeiro (1987–1991)]. Cad. Saude Publica15(3), 533–542 (1999).
   PubMedGoogle Scholar
• Düppre NC, Camacho LAB, da Cunha SS et al. Effectiveness of BCG vaccination among leprosy contacts: a cohort study. Trans. Royal Soc. Trop. Med. Hyg.102(7), 631–638 (2008).
   PubMedGoogle Scholar
• Fine PE, Ponnighaus JM, Maine N, Clarkson JA, Bliss L. Protective efficacy of BCG against leprosy in Northern Malawi. Lancet2(8505), 499–502 (1986).
   PubMedGoogle Scholar
• Goulart IM, Bernardes Souza DO, Marques CR, Pimenta VL, Goncalves MA, Goulart LR. Risk and protective factors for leprosy development determined by epidemiological surveillance of household contacts. Clin. Vaccine Immunol.15(1), 101–105 (2008).
   PubMedGoogle Scholar
• Ponnighaus JM, Fine PE, Sterne JA et al. Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi. Lancet339(8794), 636–639 (1992).
   PubMed Web of Science ®Google Scholar
• Abel L, Cua VV, Oberti J et al. Leprosy and BCG in southern Vietnam. Lancet335(8704), 1536 (1990).
   PubMedGoogle Scholar
• Baker DM, Nguyen-Van-Tam JS, Smith SJ. Protective efficacy of BCG vaccine against leprosy in southern Malawi. Epidemiol. Infect.111(1), 21–25 (1993).
   PubMedGoogle Scholar
• Bertolli J, Pangi C, Frerichs R, Halloran ME. A case–control study of the effectiveness of BCG vaccine for preventing leprosy in Yangon, Myanmar. Int. J. Epidemiol.26(4), 888–896 (1997).
   PubMedGoogle Scholar
• Boelens JJ, Kroes R, van Beers S, Lever P. Protective effect of BCG against leprosy in South Sulawesi, Indonesia. Int. J. Lepr. Other Mycobact. Dis.63(3), 456–457 (1995).
   PubMedGoogle Scholar
• Convit J, Smith PG, Zuniga M et al. BCG vaccination protects against leprosy in Venezuela: a case–control study. Int. J. Lepr. Other Mycobact. Dis.61(2), 185–191 (1993).
   PubMedGoogle Scholar
• Kerr-Pontes LR, Barreto ML, Evangelista CM, Rodrigues LC, Heukelbach J, Feldmeier H. Socioeconomic, environmental, and behavioural risk factors for leprosy in north-east Brazil: results of a case–control study. Int. J. Epidemiol.35(4), 994–1000 (2006).
   PubMedGoogle Scholar
• Lombardi C, Pedrazzani ES, Pedrazzani JC, Filho PF, Zicker F. Protective efficacy of BCG against leprosy in Sao Paulo. Bull. Pan. Am. Health Organ.30(1), 24–30 (1996).
   PubMedGoogle Scholar
• Muliyil J, Nelson KE, Diamond EL. Effect of BCG on the risk of leprosy in an endemic area: a case control study. Int. J. Lepr. Other Mycobact. Dis.59(2), 229–236 (1991).
   PubMedGoogle Scholar
• Orege PA, Fine PE, Lucas SB, Obura M, Okelo C, Okuku P. Case–control study of BCG vaccination as a risk factor for leprosy and tuberculosis in western Kenya. Int. J. Lepr. Other Mycobact. Dis.61(4), 542–549 (1993).
   PubMedGoogle Scholar
• Rahete NP, Zodpey SP, Kamble KM. Effectiveness of bacillus Calmette Guerin (BCG) vaccination in the prevention of leprosy: a population-based case–control study in Raipur, India. Indian J. Public Health51(2), 86–90 (2007).
   PubMedGoogle Scholar
• Rodrigues ML, Silva SA, Neto JC, de Andrade AL, Martelli CM, Zicker F. Protective effect of intradermal BCG against leprosy; a case–control study in central Brazil. Int. J. Lepr. Other Mycobact. Dis.60(3), 335–339 (1992).
   PubMedGoogle Scholar
• Thuc NV, Abel L, Lap VD, Oberti J, Lagrange PH. Protective effect of BCG against leprosy and its subtypes: a case–control study in southern Vietnam. Int. J. Lepr. Other Mycobact. Dis.62(4), 532–538 (1994).
   PubMedGoogle Scholar
• Zodpey SP, Ambadekar NN, Thakur A. Effectiveness of bacillus Calmette Guerin (BCG) vaccination in the prevention of leprosy: a population-based case–control study in Yavatmal District, India. Public Health119(3), 209–216 (2005).
   PubMedGoogle Scholar
• Zodpey SP, Bansod BS, Shrikhande SN, Maldhure BR, Kulkarni SW. Protective effect of bacillus Calmette Guerin (BCG) against leprosy: a population-based case–control study in Nagpur, India. Lepr. Rev.70(3), 287–294 (1999).
   PubMed Web of Science ®Google Scholar
• Zodpey SP, Shrikhande SN, Kulkarni SW, Maldhure BR. Scar size and effectiveness of bacillus Calmette Guerin (BCG) vaccination in the prevention of tuberculosis and leprosy: a case–control study. Indian J. Public Health51(3), 184–189 (2007).
   PubMedGoogle Scholar
• Zodpey SP, Shrikhande SN, Salodkar AD, Maldhure BR, Kulkarni SW. Effectiveness of bacillus Calmette–Guerin (BCG) vaccination in the prevention of leprosy; a case-finding control study in Nagpur, India. Int. J. Lepr. Other Mycobact. Dis.66(3), 309–315 (1998).
   PubMedGoogle Scholar
• Convit J, Sampson C, Zuniga M et al. Immunoprophylactic trial with combined Mycobacterium leprae/BCG vaccine against leprosy: preliminary results [see comments]. Lancet339(8791), 446–450 (1992).
   PubMedGoogle Scholar
• Chaudhury S, Hazra SK, Saha B et al. An eight-year field trial on antileprosy vaccines among high-risk household contacts in the Calcutta metropolis. Int. J. Lepr. Other Mycobact. Dis.62(3), 389–394 (1994).
   PubMedGoogle Scholar
• Truoc LV, Minh Ly H, Nguyen KT, Trach DD, Stanford CA, Stanford JL. Vaccination against leprosy at Ben San Leprosy Centre, Ho Chi Minh City, Vietnam. Vaccine19, 3451–3458 (2001).
   PubMedGoogle Scholar
• Group KPT. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group. Lancet348(9019), 17–24 (1996).
   PubMedGoogle Scholar
• Cunha SS, Alexander N, Barreto ML et al. BCG revaccination does not protect against leprosy in the Brazilian Amazon: a cluster randomised trial. PLoS Negl. Trop. Dis.2(2), e167 (2008).
   PubMedGoogle Scholar
• Shapiro S. Meta-analysis/Shmeta-analysis. Am. J. Epidemiol.140, 771–778 (1994).
   PubMed Web of Science ®Google Scholar
• Egger M, Schneider M, Davey Smith G. Meta-analysis spurious precision? Meta-analysis of observational studies. BMJ316, 140–144 (1998).
   PubMed Web of Science ®Google Scholar
• Mosteller F, Colditz GA. Understanding research systhesis (meta-analysis). Annu. Rev. Public Health17, 1–23 (1996).
   PubMed Web of Science ®Google Scholar
• Rodrigues LC, Kerr-Pontes LR, Frietas MV, Barreto ML. Long lasting BCG protection against leprosy. Vaccine25(39–40), 6842–6844 (2007).
   PubMed Web of Science ®Google Scholar
• Floyd S, Ponnighaus JM, Bliss L et al. BCG scars in northern Malawi: sensitivity and repeatability of scar reading, and factors affecting scar size. Int. J. Tuberc. Lung Dis.4(12), 1133–1142 (2000).
   PubMedGoogle Scholar
• Fine PE, Floyd S, Stanford JL et al. Environmental mycobacteria in northern Malawi: implications for the epidemiology of tuberculosis and leprosy. Epidemiol. Infect.126(3), 379–387 (2001).
   PubMedGoogle Scholar
• Fine PE. BCG: the challenge continues. Scand. J. Infect. Dis.33(4), 243–245 (2001).
   PubMed Web of Science ®Google Scholar
• Schuring RP, Richardus JH, Pahan D, Oskam L. Protective effect of the combination BCG vaccination and rifampicin prophylaxis in leprosy prevention. Vaccine27(50), 7125–7128 (2009).
   PubMed Web of Science ®Google Scholar
• Meima A, Smith WC, van Oortmarssen GJ, Richardus JH, Habbema JD. The future incidence of leprosy: a scenario analysis. Bull. World Health Organ.82(5), 373–380 (2004).
   PubMedGoogle Scholar